Member Info for LordSnooty

These questions are already resolved, Matador, so keep your sombrero on.

Yes, I see that now.

this term in the link below:
"the SAFE Agreement includes certain situations where the Long-Stop Date can be extended by 90 days to finalize and close definitive transaction documents;"
So it's possible we will have an extension RNS before next Tuesday.

If the conversion goes ahead after 21st July, and our $6m dollar SAFE note with Factom acquires going-rate + 25% shares in Series B Factom funding, I estimate that our investment in Factom, already our single largest at around 28% of portfolio, will jump to around 35%.
As commented by Paul Snow recently, things are now progressing more rapidly towards Series B Factom funding, so we are entering a very interesting period for FFWD's largest investment.
It's worth noting too that the Abony Loan to FFWD of $800k, made at the time of, and contributing towards, the SAFE note a year ago, is due for redemption on 20th July.

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/FFWD/13726698.html

And the following Tuesday, the 30th July, is Regent Pacific's EGM, to approve issue of shares for the Yooya deal.
https://www1.hkexnews.hk/listedco/listconews/sehk/2019/0711/ltn20190711259.pdf

Next Tuesday is the 23rd July, the date on which, if Factom fail to complete a financing, then the Purchase Amount will be converted to shares of a new series of preferred stock at a default price per share on the terms set forth in the SAFE agreement"
As Kierewiet pointed out two weeks ago, "if the $6 million SAFE is converted to preferred stock and series B is subsequently completed a few months later at a significant premium to this default price, it could be very good news for FFWD. Not sure how realistic this is though."

Doesn't the Factom option that someone mentioned a couple of weeks ago lapse in the next day or two?

£400m would value our stake at £10.4m, or about 6.25p/share to the NAV.

This from a February Times article:
"A medicinal cannabis start-up is eyeing a London float in what could be the first in a wave of listings amid rapid deregulation.
Emmac Life Sciences is believed to be working with broker Canaccord Genuity on a listing that could value it at £400m. Led by Antonio Costanzo, who previously worked at the Toronto-listed cannabis producer Nuuvera, Emmac was set up last year and aims to become Europe’s leading supplier and producer of the drug...."

With news of today's acquisition.

With EMMAC's Portuguese acquision today, and a now fully integrated European supply chain, it's possible that the Chairman's forward-looking statement in Finals will give some pointers as to how our EMMAC holding's value is faring.

You may wish to watch closely if you are serious about buying, ODONNELLS - I am quoted 8.38/8.6139 with IG. It seems to me this is now being well bid, and hence that (good) news is anticipated.

I like the fact that MMs have walked this down from the 40% rise of a couple of weeks ago too - any rise on the back of good news will be that much more sustainable from hereabouts.

Nice one, Rich; that kind of detail is impressive - and probably wrong. But I'm prepared to eat my bowler.

Good to see you alive and well, Dogs. You could be right about news, but I'm going to take your 11.97p and up you 0.18p to 12.15p, because I think Leap will show another good increase in NAV.

for next leg. Absorbing the short-term trader sells. Finals expected imminently, I think.

https://www.zerohedge.com/news/2019-07-13/healthcare-providers-canada-turn-cbd-help-difficult-dementia-symptoms

delayed slightly on account of expected news tardy in arriving. ETA next week.

Where would we be without the ODONNELLS?

We have to accept that that's AIM, Doggo. That brings us full circle, back to the old short-term/long-term debate; on balance I'm in the latter camp, especially with this fund/stock, but I can understand why so many are short-term in this market, given the volatility and the frustrations.